- Home
- PAYS vs GNLX Comparison
PAYS vs GNLX Comparison
Compare PAYS & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYS
- GNLX
- Stock Information
- Founded
- PAYS 2001
- GNLX 2001
- Country
- PAYS United States
- GNLX United States
- Employees
- PAYS N/A
- GNLX N/A
- Industry
- PAYS Business Services
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- PAYS Consumer Discretionary
- GNLX Health Care
- Exchange
- PAYS Nasdaq
- GNLX Nasdaq
- Market Cap
- PAYS 125.2M
- GNLX 128.0M
- IPO Year
- PAYS 1998
- GNLX 2023
- Fundamental
- Price
- PAYS $5.82
- GNLX $4.14
- Analyst Decision
- PAYS Strong Buy
- GNLX Strong Buy
- Analyst Count
- PAYS 4
- GNLX 4
- Target Price
- PAYS $7.31
- GNLX $17.75
- AVG Volume (30 Days)
- PAYS 704.8K
- GNLX 151.7K
- Earning Date
- PAYS 11-04-2025
- GNLX 11-13-2025
- Dividend Yield
- PAYS N/A
- GNLX N/A
- EPS Growth
- PAYS N/A
- GNLX N/A
- EPS
- PAYS 0.12
- GNLX N/A
- Revenue
- PAYS $68,539,381.00
- GNLX N/A
- Revenue This Year
- PAYS $35.12
- GNLX N/A
- Revenue Next Year
- PAYS $20.99
- GNLX N/A
- P/E Ratio
- PAYS $47.68
- GNLX N/A
- Revenue Growth
- PAYS 27.84
- GNLX N/A
- 52 Week Low
- PAYS $1.80
- GNLX $1.95
- 52 Week High
- PAYS $8.88
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- PAYS 55.64
- GNLX 64.68
- Support Level
- PAYS $5.08
- GNLX $3.76
- Resistance Level
- PAYS $5.56
- GNLX $4.21
- Average True Range (ATR)
- PAYS 0.21
- GNLX 0.26
- MACD
- PAYS -0.21
- GNLX 0.05
- Stochastic Oscillator
- PAYS 97.08
- GNLX 92.31
About PAYS Paysign Inc.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.